Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDT and SDT with Hematoporphyrin for Inoperable Cholangiocarcinoma
NCT05580328Unknown
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Dec 2022
- Primary completion
- Oct 2024
- Modality
- Light/Condition-Responsive Prodrugs
01
Overview
Open-label, single-arm trial of hemoporfin in cholangiocarcinoma (CCA), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Size of tumor evaluated by CT at 24 months. Status: unknown.
02
Drugs
hemoporfin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05580328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05580328.